A synthetic antigen containing the presumed receptor site for wheat-germ agglutinin ( Evidence has been accumulating over a period of many years to indicate that the primary host defense against malignancy is a cell-mediated immune response mounted against tumorspecific surface antigens (1). However, the promise of immunotherapy for the control of cancer has resisted practical exploitation because of two problems. The first problem is immunological enhancement of tumor growth: if a humoral immune response, especially that of IgG, is mounted against the surface antigens, it blocks the action of the cellular immune system, and the rate of growth of the tumor is enhanced (2). The second problem is that the number of distinct tumor-specific surface antigens is very large (3), so that immunization against one tumor type affords little or no protection against all other tumor types (4).
immune response in mice capable of cross-reacting with receptor sites for wheat-germ agglutinin on tumor-cell surfaces. Mice immunized against the antigen in complete Freund's adjuvant are able to reject five times as many transplanted myeloma tumor cells as are rejected by otherwise identically treated control mice. Methylcholanthrene-induced tumors appear later in mice immunized against the antigen than in controls. The protection of mice against tumor transplants can be transferred to unimmunized mice with spleen cells, but notwith serum from immunized donors. Immunization of mice against the wheat-germ agglutinin receptor seemed to have no marked deleterious effect on biological processes in normal dividing cells.
Evidence has been accumulating over a period of many years to indicate that the primary host defense against malignancy is a cell-mediated immune response mounted against tumorspecific surface antigens (1) . However, the promise of immunotherapy for the control of cancer has resisted practical exploitation because of two problems. The first problem is immunological enhancement of tumor growth: if a humoral immune response, especially that of IgG, is mounted against the surface antigens, it blocks the action of the cellular immune system, and the rate of growth of the tumor is enhanced (2) . The second problem is that the number of distinct tumor-specific surface antigens is very large (3) , so that immunization against one tumor type affords little or no protection against all other tumor types (4) .
In contrast to this diversity, virtually all tumor cell lines can be agglutinated about ten times as effectively as normal cell lines by a lectin, wheat-germ agglutinin (5, 6) (WGA). As a result of studies on the binding of fluorescein-labeled WGA to fibroblasts, Box et al. (7) have interpreted the specific agglutination in terms of WGA receptor sites present on the surface of tumor cells at all times, but present on the surface of normal cells only during cell division.
In this paper I report the application of the so-called "chemical vaccine" approach of immunoparisitology (8) to the cancer problem. As strictly applied to the cancer problem, this approach would involve isolating from the surfaces of tumor cells the antigenic determinants of the tumor-specific surface antigens, determining their structures, and synthesizing them in an immunogenic form. However, the discovery of a WGA receptor site common to virtually all tumor cells suggests a solution to the problem caused by the diversity of the surface antigens. The results presented in this paper, although preliminary, indicate that the WGA receptor sites can be used as tumor antigens.
From agglutination-inhibition studies performed by Burger, one can infer the chemical structure of the receptor site for which WGA is specific (5) . The agglutination of tumor cells by WGA was inhibited by N-acetylglucosamine (GlcNAc) and about ten times as effectively, on a molar basis, by the disaccharide of GlcNAc, di-N-acetylchitobiose (5). However, N-acetylchitodextrins (higher homologs of GlcNAc) are not more effective on a molar basis than di-N-acetylchitobiose (9) , which suggests that WGA is specific only for the disaccharide. Burger (10) has isolated the WGA receptor site from the surface of tumor cells, and shown it to be a soluble glycoprotein containing GlcNAc.
In all soluble glycoproteins that have been studied to date, when GlcNAc is found at the carbohydrate-protein linkage, it is linked O-D-glucosidically to the amide group of an -asparagine (11) . Presumably the same linkage is found in the WGA receptor protein, and hence the receptor site has the partial structure shown in Fig. 1 .
I have prepared a synthetic antigen designed to elicit an immune response able to crossreact with the WGA receptor site on tumor cells. Preliminary evidence indicates that progression of tumors of a wide range of antigenic specificity is retarded in mice immunized with this antigen. It is possible that modification of the antigen, adjuvant, and immunization schedule will ultimately permit the development of a vaccine that will elicit a strong protective cellular immune response with a negligible humoral response. The following immunization schedules have been used: I, The antigen solution (10 /Ag/ml) was emulsified in 3 volumes of complete Freund's adjuvant; a subcutaneous injection of 0.1 ml in each groin was repeated at 2 weeks and the mice were challenged at 6 weeks. II, The antigen solution (100 /Ig/ml) was processed as in I; an intraperitoneal injection of 0.1 ml as well as a subcutaneous injection of 0.1 ml in each groin was followed at 2 and 4 weeks with subcutaneous injections of 0.1 ml in each groin, and the mice were challenged at 6 weeks. III, The same as schedule II, except that no intraperitoneal injection was administered. IV, The same as schedule I, except that antigen solutions at 100 Ag/ml were used and the booster injections were given at 3 weeks. V, The same as schedule II, except that antigen solutions at 500 ,ug/ml were used. VI, The same as schedule I, except that there was no boost at 2 weeks and the mice were challenged at 3 weeks.
Pooled spleen-cell suspensions were prepared immediately after removal of the spleens by teasing the spleens apart in Eagle's medium, and passing the resulting suspension through a sterile 200-mesh stainless steel screen. The number of viable nucleated cells was counted at a 1: 100 dilution in 0.05% Trypan blue (Matheson, Coleman and Bell) in 2% acetic acid in saline. The number of direct plaque-forming cells was determined by the method of Jerne and Nordin (12) . The number of rosette-forming cells was determined by the method of Cone and Johnson (13) using suspensions of 6 X 106 spleen cells/ml and 48 X 106 sheep erythrocytes per ml. (16) . A better synthesis of this intermediate has subsequently appeared in the literature (15) . The glycosyl azide was de-O-acetylated by the method of Michael and Wulff (17) , and the crude product was hydrogenated over platinum black (16) The antigen, A, was prepared as follows: sodium poly(Laspartate) [34.5 mg, prepared from poly(iaspartic acid) (Sigma) by dissolving a sample in 0.1 M sodium carbonate followed by dialysis and lyophilization], compound I (120 mg), ethylenediamine (0.1 mg), and the coupling compound 1 -ethyl-3(3-dimethylaminopropyl) -carbodimide hydrochloride (ECDI) (100 mg, Sigma) were dissolved in 1 ml of water and allowed to stand at room temperature for 1 week. The solution was dialyzed against 10% NaCl and then water, and lyophilized to yield 33.5 mg of A containing about 13% substitution of available carboxyl groups as determined by aminoacid analysis. The control antigen, B, was prepared in an identical manner except that no compound I was added to the reaction mixture. bovine serum albumin (MBSA, Sigma) were prepared by dropwise addition of a 1% solution of the latter to 20 volumes of a stirred solution of the antigen in water (0.5 mg/ml). The resulting suspension was sonicated to disperse the precipitate and diluted.
RESULTS
One synthetic antigen that could be expected to elicit an immune response against the partial structure given in Figure 1 is composed of poly(L-aspartic acid) having some of the free carboxyl groups substituted with a sugar moiety. The simplest way to prepare such an antigen (18) is to link the glycosylamine via a peptide linkage to free carboxyls of poly(i, aspartate) (Fig. 2) . In practice, up to 13% of available carboxyl groups were substituted with the sugar moiety. Ethylenediamine was added to the reaction mixture as a crosslinking agent intended to increase the molecular weight and therefore the immunogenicity of the antigen, A. The crosslinked polypeptide backbone, B, was prepared under identical conditions for use as a control antigen.
Two types of experiments indicate that WGA has a specific affinity for A. As shown in Fig. 3 WGA has a high degree of specificity for a structure present in A, but not in B. The hemagglutination-inhibition results further indicate that WGA is specific for a structure somewhat larger than the disaccharide, possibly as large as the structure presented in Fig. 1 , and this structure is almost as large as the poly(iasparate) antigenic determinant at the early stages of the immune response (19) . Tables 2 and 3 suggest that beyond some optimum conditions, immunization with more antigen and injections result in less protection. It may be that more vigorous immunization causes an enhancing humoral immune response that competes with cell-mediated protection. It should be noted that the minimum numbers of XS63 -5 cells required to cause a tumor cannot be meaningfully compared from experiment to experiment, since this number is highly dependent on the age of the mice and state of the cells at the time of challenge.
The appearance of palpable tumors induced by 3-methylcholanthrene, which is known to induce localized tumors with a large degree of antigenic variation (3) , is delayed in groups of mice immunized against A (MBSA), relative to unimmunized mice and mice immunized against B(MBSA) (Fig.  4) . The close correspondence of the aged control and anti-B(MBSA) curves in Fig. 4A suggest that the amount of protection due to general immunological stimulation by complete Two lines of evidence suggest that the observed protection is mediated by specific action of the immune system. First, some protection can be transferred from donor to unimmunized mice with spleen cells, while a degree of enhancement is transferred with serum (Table 4) . Immunization schedule II, which does not stimulate a net protection in immunized mice (Table 3) , was selected to produce a set of donors capable of donating both protection and enhancement of tumor growth to unimmunized recipients. Second, a single injection of 0.5 /ug of A (MBSA) stimulates a degree of protection 3 weeks later (Table 3) . This represents treatment with quantities of A (MBSA) substantially lower than would be expected to be required were it acting as a chemotherapeutic agent and than that required for general immunological stimulation by another polysaceharide, lentinan, which required 200 ,ug in 10 daily injections beginning at the time of challenge with tumor cells (21) .
If the observation of Box et al. (7) that the WGA receptor site is present on untransformed fibroblasts in mitosis is true for all types of untransformed cells, immunization of an animal against this structure might cause destruction of normal dividing cells. Three phenomena that result from normal cell division were compared ( (12) , the rosette assay (22) , and the hemagglutination titer. The cellular immune response was evaluated by determining the survival time of C57B1/6J skin allografts.
No marked effect on either immune system was observed, although the results suggest that a greater degree of suppression of cellular immune response occurs in mice immunized against A (MBSA). Wound healing was evaluated by comparing the rates of liver regeneration after partial hepatectomy. A small, but probably real, reduction in the rate of liver regeneration was observed.
DISCUSSION The experiments employed a massive dose of a very potent carcinogen, which presumably transforms many normal cells in each mouse. Most are destroyed by the immune system, but even in immunized mice, transformed cells ultimately escape the immune system and develop into palpable tumors. The delay in appearance of palpable tumors in immunized mice perhaps reflects the greater number of transformants eliminated by the immune surveillance system when it is agumented by circulating memory cells (23) specific for the WGA receptor site. In complement-deficient mice, such as the BALB/c mice used in these experiments, or in animals mounting only a cellular immune response to the WGA receptor site, attack on normal cells might be expected to occur only during rapid, localized cell division. Typically, a cell would be expected to pass through mitosis (about 1 hr) before any delayed hypersensitive response that it might stimulate could be carried out against it (about 18 hr). Only if there were another dividing cell nearby would the response be expected to continue and lead to cell destruction. These conditions may be met in liver regeneration.
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